Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
BerGenBio ASA ( (BRRGF) ) has issued an announcement.
Oncoinvent ASA has announced an extraordinary general meeting on December 5, 2025, to approve key actions related to a NOK 130 million rights issue. This includes the approval of an audited interim balance sheet, a share capital reduction, and ratification of a previous resolution to increase share capital. The meeting will be held electronically, reflecting the company’s strategic financial maneuvers to support its ongoing clinical trials and development of Radspherin®, a promising cancer treatment currently in a randomized Phase 2 trial.
The most recent analyst rating on (BRRGF) stock is a Buy with a NOK38.00 price target. To see the full list of analyst forecasts on BerGenBio ASA stock, see the BRRGF Stock Forecast page.
More about BerGenBio ASA
Oncoinvent is a clinical-stage biotechnology company focused on developing novel radiopharmaceutical therapies against cancer. Its lead product, Radspherin®, targets micro-metastases in the peritoneum post-surgery using radium-224, offering a unique therapeutic approach with promising early clinical efficacy data.
Average Trading Volume: 217,315
Current Market Cap: NOK266.7M
Find detailed analytics on BRRGF stock on TipRanks’ Stock Analysis page.